Cipla expects sales of branded generics to cross $1 billion this fiscal
![](https://img.etimg.com/thumb/msid-87450246,width-1070,height-580,imgsize-106914,overlay-economictimes/photo.jpg)
Cipla's branded generics business reported sales of around ₹6,000 crore in FY21. The drug maker's India business, which consists of prescription, trade generics and consumer health divisions, generated sales of ₹5,126 crore in the first half of this fiscal year, compared with ₹3,698 crore in H1FY21, an increase of 39%.
via Economictimes
Post a Comment